Anti Venom Market, By Anti-venom Type (Polyvalent and Monovalent), By Product Type (Snake Antivenom, Scorpion Anti-venom, Spider Anti-venom, Others), By End User (Hospitals & clinics, Ambulatory Surgical Centers, Research Institutes, Others), By Geography

Anti Venom Market, By Anti-venom Type (Polyvalent and Monovalent), By Product Type (Snake Antivenom, Scorpion Anti-venom, Spider Anti-venom, Others), By End User (Hospitals & clinics, Ambulatory Surgical Centers, Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global anti venom market growth is driven by rising incidence of snake bites and scorpion stings across tropical and sub-tropical regions of the world. Each year over 5 million

people are bitten by snakes, out of which, around 2.7 million cases result in envenoming and around 100,000 deaths. There has been rising demand for anti-venom as the availability of effective anti-venoms has improved survival and recovery rates for victims of snake bites in many countries. Leading manufacturers are engaging in development of novel anti-venoms through reforms in production techniques using modern immunological and biochemical methods. Rising investments towards building awareness about timely treatment and availability of anti-venoms can also drive the market growth.

Market Dynamics:

Global anti venom market growth is primarily driven by increasing incidence of snake bites and scorpion stings globally. According to the World Health Organization, around 5.4 million people suffer from snake bites each year and about 2.7 million are envenomed with around 137,000 deaths. Rising investments by market players and governments towards educating rural populations, improving access to healthcare facilities and ensuring availability of anti-venoms across remote areas can offer lucrative opportunities. However, high costs of anti-venoms, short shelf-life requiring constrained and controlled storage and transportation can limit its widespread adoption. Lack of awareness, traditional beliefs and geographical barriers restrict timely treatment seeking for victims in developing nations. Market players involved in research and production of innovative, more effective and affordable anti-venoms can offer market growth opportunities.

Key features of the study:

• This report provides in-depth analysis of the global anti venom market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti venom market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bharat Serums & Vaccines, Haffkine Bio-Pharmaceutical Corporation, Vins Bioproducts, Bharat Biotech, and Serum Institute of India
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global anti venom market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti venom market

Detailed Segmentation-

• By Anti-venom Type
• Polyvalent
• Monovalent
• By Product Type
• Snake Antivenom
• Scorpion Anti-venom
• Spider Anti-venom
• Others
• By End User
• Hospitals & clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others
• By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Pfizer, Inc.
• Merck & Co., Inc.
• Sanofi Pasteur
• 4CSL Limited
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• Instituto Bioclon S.A. de C.V.
• Rare Disease Therapeutics, Inc.
• Vins Bioproducts Limited
• Bharat Serums and Vaccines Limited
• Serum Institute of India Pvt. Ltd.
• Incepta Pharmaceuticals Ltd.
• MicroPharm Limited
• Laboratorios Silanes S.A.
• BTG plc
• Vacsera
• Indian Immunologicals Limited
• AfrIPI (African Institute of Biomedical Science and Technology)